Plasma disposition and tissue depletion of chlortetracycline in the food producing animals, chickens for fattening

被引:24
作者
Anadon, Arturo [1 ]
Gamboa, Felipe [1 ]
Aranzazu Martinez, Maria [1 ]
Castellano, Victor [1 ]
Martinez, Marta [1 ]
Ares, Irma [1 ]
Ramos, Eva [1 ]
Suarez, Frank H. [1 ]
Rosa Martinez-Larranaga, Maria [1 ]
机构
[1] Univ Complutense Madrid, Dept Pharmacol & Toxicol, Fac Vet Med, E-28040 Madrid, Spain
关键词
Chlortetracycline; Plasma and tissue depletion; Withdrawal time; Chickens for fattening; TETRACYCLINE RESISTANCE; ESCHERICHIA-COLI; CITRIC-ACID; PHARMACOKINETICS; SUSCEPTIBILITY; PHARMACODYNAMICS; BIOAVAILABILITY; DOXYCYCLINE; OXYTETRACYCLINE; ANTIBIOTICS;
D O I
10.1016/j.fct.2012.05.007
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Chickens were used to investigate plasma disposition of chlortetracycline after single IV (15 mg/kg) and multiple oral administration (60 mg/kg, 5 days) and residue depletion of chlortetracycline after multiple oral doses (60 mg/kg, 5 days). Plasma and tissue samples were analyzed by HPLC. Mean elimination half-lives in plasma were 7.96 and 13.15 h after IV and multiple oral administration. Maximum plasma concentration was 4.33 mu g/ml and the interval from oral administration until maximal concentration was 1.79 h. Oral bioavailability was 17.76%. After multiple oral dose, mean kidney, liver and muscle tissue concentrations of chlortetracycline + 4-epi-chlortetracycline of 835.3, 192.7, and 126.3 mu g/kg, respectively, were measured 1 day after administration of the final dose of chlortetracycline. Chlortetracycline residues were detected in kidney and liver (205.4 and 81.7 mu g/kg, respectively), but not in muscle, 3 days after the end of chlortetracycline treatment. The mean chlortetracycline + 4-epi-chlortetracycline concentrations were below LOQ at 3 and 5 days after cessation of medication in muscle and liver, respectively. A withdrawal time of 3 days was necessary to ensure that the chlortetracycline residues were less than the maximal residue limits (MRLs) established by the European Union (100, 300, and 600 mu g/kg in muscle, liver, and kidney, respectively). (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2714 / 2721
页数:8
相关论文
共 46 条
[11]   The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis [J].
Burgess, D. S. ;
Frei, C. R. ;
Lewis, J. S., II ;
Fiebelkorn, K. R. ;
Jorgensen, J. H. .
CLINICAL MICROBIOLOGY AND INFECTION, 2007, 13 (01) :33-39
[12]  
Cerdá RO, 2002, AVIAN DIS, V46, P215, DOI 10.1637/0005-2086(2002)046[0215:IVASOF]2.0.CO
[13]  
2
[14]   Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance [J].
Chopra, I ;
Roberts, M .
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 2001, 65 (02) :232-+
[15]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[16]   Pharmacodynamics of doxycycline [J].
Cunha, BA ;
Domenico, P ;
Cunha, CB .
CLINICAL MICROBIOLOGY AND INFECTION, 2000, 6 (05) :270-273
[17]   Prevention of resistance: A goal for dose selection for antimicrobial agents [J].
Drusano, GL .
CLINICAL INFECTIOUS DISEASES, 2003, 36 :S42-S50
[18]  
DYER DC, 1988, AM J VET RES, V49, P36
[19]  
EISNER HJ, 1963, J PHARMACOL EXP THER, V142, P122
[20]  
EMEA (The European Agency for the Evaluation of Medicinal Products), 1995, EMEAMRL02395 EUR AG